13.40USD-2.55%Mkt Cap: 1.40B $P/E: —1d ago
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of mi…
Industry Peers
Diagnostics & Researchvs Diagnostics & Research
P/B
Pricier
1M Perf
Lower
$186.32BUSDP/E 27.6
$134.82BUSDP/E 36.8
$43.51BUSDP/E 42.0
$41.53BUSDP/E 38.7
$38.88BUSD
$37.53BUSDP/E 26.7
$36.82BUSDP/E 47.7
$32.25BUSDP/E 24.0
$26.60BUSDP/E 31.9
$25.82BUSDP/E 30.0
$23.46BUSDP/E 23.4
$22.96BUSDP/E 24.8
$19.89BUSD
$15.12BUSDP/E 33.3
$12.91BUSDP/E 26.9
$12.41BUSDP/E 53.5
$10.92BUSD
$8.81BUSDP/E 20.6
$6.41BUSD
$5.52BUSDP/E 222.2
$5.06BUSDP/E 43.3
$4.85BUSD
$4.69BUSDP/E 54.4
$3.65BUSDP/E 25.7
$3.43BUSD
$2.93BUSD
$2.04BUSD
$1.90BUSD
$1.48BUSDP/E 37.4
$1.48BUSDP/E 22.4
$1.47BUSD
$1.13BUSD
$1.01BUSDP/E 21.1
$723.37MUSD
$615.20MUSDP/E 40.1
$582.78MUSD
$539.30MUSD
$297.38MUSDP/E 3.0
$282.06MUSD
$233.52MUSD
$190.51MUSD
$147.80MUSD
$112.34MUSD
$94.30MUSDP/E 18.2
$77.88MUSD
$58.94MUSD
$44.26MUSD
$27.97MUSD
$27.15MUSD
$22.69MUSD
$17.60MUSD
$12.55MUSD
$10.07MUSDP/E 63.2
$9.85MUSD
$9.02MUSD
$8.78MUSD
$6.77MUSD
$6.29MUSD
$5.98MUSD
$5.10MUSD
$4.66MUSD
$3.81MUSD
$3.86MUSDP/E 2.8
$2.93MUSD
$2.79MUSD
$2.43MUSD
$1.29MUSD
$314.2KUSDP/E Infinity
$14.0KUSD
Indicators:|
Key Statistics
Company
Market Cap1.40B $
Enterprise Value1.21B $
Revenue (TTM)64.52M $
Gross Profit15.78M $
Net Income (TTM)-81.27M $
Revenue/Share0.6910 USD
Last Price13.40 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees259
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.96
PEG—
EV/EBITDA-13.03
EV/Revenue18.72
P/S21.75
P/B5.51
EPS (TTM)-1.02
EPS (Forward)-0.90
52W Range
3.84093% of range14.07
52W High14.07 USD
52W Low3.840 USD
Profitability
Gross Margin22.65%
Oper. Margin-207.87%
EBITDA Margin-143.68%
Profit Margin-116.69%
ROE-31.12%
ROA-24.32%
Growth
Revenue Growth-24.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-74.95M $
CapEx (TTM)4.50M $
FCF Margin-65.65%
FCF Yield-3.02%
Net Debt-194.44M $
Net Debt/EBITDA2.10
Balance Sheet
Debt/Equity0.15
Current Ratio6.61
Quick Ratio6.31
Book Value/Sh2.433 USD
Cash/Share2.227 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)10.86 USD
Upside (mean)-19.0%
Target Range9.000 USD – 13.00 USD
$9.000-19.0% to mean$13.00
# Analysts7
Ownership
Shares Out.104.72M
Float64.53M
Insiders27.05%
Institutions68.19%
Short Interest
Short Ratio3.7d
Short % Float16.75%
Short % Out.10.60%
Shares Short11.10M
Short (prev mo.)13.73M
Technical
SMA 508.412 (+59.3%)
SMA 2008.253 (+62.4%)
Beta2.28
S&P 52W Chg20.05%
Avg Vol (30d)3.15M
Avg Vol (10d)4.01M
Technical Indicators
RSI (14)72.4
MACD1.1484
MACD Signal0.8758
MACD Hist.+0.2726
BB Upper13.63 USD
BB Middle10.86 USD
BB Lower8.092 USD
BB Width50.99%
ATR (14)1.005 USD
Vol Ratio (20d)0.99x